All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news

RSS

← First12345...704Next →

hiv & aids news selected from other sources

  • Men who have sex with men (MSM)
    Call for same-sex SRE be statutory in all English schools
    NAT press release | 15 hours ago

    A coalition of LGBTI (Lesbian Gay Bisexual Trans Intersex) organisations and campaigners have written an open letter to political leaders in the UK, highlighting the urgent need to make Sex and Relationship Education (SRE) statutory in all schools – as well as appropriate for LGBTI young people.

  • HIV prevention policy
    Why Are HIV Rates So High in Russia?
    International Business Times | 15 hours ago

    Russia is home to one of the fastest-growing HIV and AIDS epidemics in the world, abetted by policies that promote infections rather than curbing them.

  • Hepatitis C treatment
    Gilead Deal to Sell Sovaldi in Poor Countries Meets Criticism
    Pharmalot | 15 hours ago

    more than three dozen patient advocacy groups say the licensing deals do not go far enough, because the deals excludes many middle-income countries – such as Brazil, China, Turkey, Thailand and Ukraine – where governments and individuals may not be able to afford the Gilead drug. The patient groups are concerned the licenses will preclude the generic drug makers from selling lower-cost versions to those countries and potentially excluding millions of patients with hepatitis C from gaining access to treatment.

  • New and experimental HIV treatments
    First Single-Tablet PI Regimen With Darunavir and TAF at 48 Weeks
    NATAP | 21 hours ago

    Cobicistat-boosted darunavir plus tenofovir alafenamide (TAF) and emtricitabine (FTC) yielded less bone and renal toxicity than darunavir/cobicistat plus tenofovir/emtricitabine (TDF/FTC) in randomized a phase 2 trial.

  • PEP
    What to Do When a Patient Admits an H.I.V. Phobia
    New York Times | 21 hours ago

    She had been volunteering at a drop-in center for the homeless, helping to prepare dinner, when she felt a sting in the tip of the finger and looked down to see a red mark and a dot of blood. She could not find the object that had poked her, but she knew immediately what might have happened: She had seen a few used syringes lying around the place, and perhaps one had somehow gotten into the sink and perhaps she had stuck her finger with it, and perhaps it had just been used by an H.I.V.-infected addict, and perhaps right that minute, the virus was coursing through her own veins. So of course she went to the nearest emergency room. She knew that medication taken promptly could prevent H.I.V., and she wasn’t taking any chances.

  • Hepatitis C treatment
    Clash between state, drugmaker heats up as Legislature takes up Hepatitis C cost
    The Oregonian | 21 hours ago

    Citing the 12-week treatment cost of $84,000, Oregon officials want to put strict new restrictions on access to the drug, especially for those in earlier stages of the disease. Commercial insurers already have some access rules, but are watching the state's battle closely.

  • Side-effects
    Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep
    NATAP | 22 hours ago

    Switching from Atripla (efavirenz plus tenofovir/emtricitabine [TDF/FTC]) to Complera (Eviplera, rilpivirine plus TDF/FTC) significantly relieved central nervous system (CNS) toxicity and improved sleep in people with those problems while taking Atripla [1]. All but 1 of 40 study participants who switched in this London/Brighton study maintained virologic control through 24 weeks.

  • Hepatitis C treatment
    Gilead signs pact with 7 firms for cheap copies of hepatitis C drug
    Reuters | 15 September 2014

    Gilead's licensing agreement with firms including India's Cipla Ltd and Ranbaxy Laboratories Ltd clears the way for the launch of a cheap generic version of the drug in 91 developing countries that make up 54 percent of the total global hepatitis burden.

  • Promoting HIV testing
    New “peer navigator” program encourages at-home HIV testing
    Oakland North | 15 September 2014

    A new study using networks of friends as “peer navigators” will soon be launched in the East Bay to reach men who may be vulnerable to the AIDS virus. It’s part of an effort to make better use of confidential in-home HIV testing in order to reach at-risk populations in Oakland.

  • PrEP
    HIV-fighting intravaginal ring research nets $20M from NIH
    Fierce Drug Delivery | 15 September 2014

    The U.S. National Institutes of Health devoted $20 million to a group of institutions including Miriam Hospital in Rhode Island to develop an HIV drug-delivering intravaginal ring. The design of a successful ring is a priority in HIV research, and the sustained release of drugs the ring offers could eventually play a crucial role in HIV prevention in the developing world.

← First12345...938Next →

Hepatitis C news

WHO recommends global use of newest hepatitis C drugs, urges price reductions.

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.

Treatment as prevention

No-one with an undetectable viral load, gay or heterosexual, transmits HIV in two years of PARTNER study.

aidsmap news apps

Download the free aidsmap news iPhone and android apps.